Clinical Trial Update: Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer [Phase 1]

View source ↗

Summary

A Phase 1 safety and efficacy study of CC-122 in combination with sorafenib for hepatocellular carcinoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• CC-122
• Sorafenib (Sorafenib)

Snippet

Sponsor: Celgene | Conditions: Carcinoma, Hepatocellular | Phase 1 | Status: TERMINATED